Dr Lal PathLabs Q2 FY27: Revenue Rs 874.00 cr, PAT Rs 194.00 cr; margins rise YoY
Dr. Lal PathLabs’ consolidated Q2 FY27 revenue rose to Rs 874.00 cr from Rs 731.00 cr and PAT to Rs 194.00 cr from Rs 152.00 cr, with EBITDA margin at 32.1% versus 30.7% a year ago.
Key takeaways
- Revenue Rs 874.00 cr in Q2 FY27, up from Rs 731.00 cr in Q2 FY26.
- EBITDA Rs 280.00 cr in Q2 FY27, vs Rs 224.00 cr in Q2 FY26.
- PAT Rs 194.00 cr in Q2 FY27, compared with Rs 152.00 cr in Q2 FY26.
- EBITDA margin 32.1% in Q2 FY27, vs 30.7% in Q2 FY26.
- EPS (Basic) 11.5 in Q2 FY27, vs 9.0 in Q2 FY26.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 874.00 cr | Rs 731.00 cr | +19.6% |
| PAT | Rs 194.00 cr | Rs 152.00 cr | +27.5% |
| Margin | 22.2% | 20.8% | +140 bps |
As reported in the filing. Figures are transcribed, not computed.
-
Basis & period reported: Consolidated financials for Q2 FY27 (quarter ended 30 September 2026), compared with Q2 FY26, as per the statement of financial results in the earnings presentation.
-
Revenue: Rs 874.00 cr in Q2 FY27, up from Rs 731.00 cr in Q2 FY26 (statement of financial results – “Revenue”).
-
Total income: Not separately labelled as a single line in the statement of financial results in the presentation; revenue is the primary top-line figure disclosed.
-
Total expenses (key components):
- Material consumed: Rs 162.00 cr in Q2 FY27, vs Rs 142.00 cr in Q2 FY26.
- Employee benefit Expenses: Rs 139.00 cr in Q2 FY27, vs Rs 124.00 cr in Q2 FY26.
- Fees to collection centres: Rs 129.00 cr in Q2 FY27, vs Rs 109.00 cr in Q2 FY26.
- Other Expenses: Rs 164.00 cr in Q2 FY27, vs Rs 132.00 cr in Q2 FY26.
-
EBITDA: Rs 280.00 cr in Q2 FY27, vs Rs 224.00 cr in Q2 FY26 (statement of financial results – “EBITDA”).
-
PBT: Rs 261.00 cr in Q2 FY27, vs Rs 204.00 cr in Q2 FY26 (statement of financial results – “PBT”).
-
PAT: Rs 194.00 cr in Q2 FY27, vs Rs 152.00 cr in Q2 FY26 (statement of financial results – “PAT”).
-
Margins (as printed):
- EBITDA margin: 32.1% in Q2 FY27, vs 30.7% in Q2 FY26.
- PBT margin: 29.8% in Q2 FY27, vs 27.9% in Q2 FY26.
- PAT margin: 22.2% in Q2 FY27, vs 20.8% in Q2 FY26.
-
Other income, depreciation, finance cost:
- Other Income: Rs 34.00 cr in Q2 FY27, vs Rs 25.00 cr in Q2 FY26.
- Depreciation Cost: Rs 47.00 cr in Q2 FY27, vs Rs 41.00 cr in Q2 FY26.
- Finance Cost: Rs 7.00 cr in Q2 FY27, vs Rs 5.00 cr in Q2 FY26.
-
Tax expense: Income Tax of Rs 67.00 cr in Q2 FY27, vs Rs 51.00 cr in Q2 FY26.
-
Earnings per share: EPS (Basic) of 11.5 in Q2 FY27, vs 9.0 in Q2 FY26.
For the half year, the same consolidated statement of financial results in the presentation shows H1 FY27 revenue at Rs 1,672.00 cr versus Rs 1,400.00 cr in H1 FY26, EBITDA at Rs 528.00 cr versus Rs 416.00 cr, PBT at Rs 489.00 cr versus Rs 385.00 cr, and PAT at Rs 364.00 cr versus Rs 286.00 cr. The company also prints H1 FY27 EBITDA margin at 31.6% (29.7% in H1 FY26), PBT margin at 29.3% (27.5% in H1 FY26) and PAT margin at 21.8% (20.4% in H1 FY26), along with EPS (Basic) of 21.7 in H1 FY27 compared with 17.0 in H1 FY26.
The note under the financials table in the statement of financial results states that figures for the current quarter and the corresponding period last year have been reclassified and regrouped for better operational clarity and comparability, and that financial results are best monitored on a year-to-date basis due to seasonality and quarter-specific factors.
Get Dr. Lal PathLabs Ltd's next results the minute they're filed
Results reach the exchange at all hours, most of them after the market closes. Pro puts the filing in your feed as it is published, with our read of the numbers. A free account sees it an hourback for a day.
- We'll start you off following LALPATHLAB.
- 14 days free, no card. After that you keep a free account.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.